Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

SHTAC is critically appraising the company’s submission to NICE on nintedanib for treating idiopathic pulmonary fibrosis

Published: 11 May 2015
There is currently no cure for IPF

SHTAC is assessing the company's evidence submission to the National Institute for Health and Care Excellence (NICE) on the clinical and cost effectiveness of nintedanib for treating idiopathic pulmonary fibrosis (IPF), as part of NICE’s Single Technology Appraisal process.

Around 5000 people in the UK are diagnosed with IPF each year. IPF, which most commonly affects people over the age of 60, is a chronic, progressive condition in which the lungs become inflamed and scarred and eventually lose function over time. The exact cause of IPF is unknown, but it is thought that it results from recurrent injury to the lung cells from, for example, exposure to viruses or cigarette smoking. Common symptoms include breathlessness and cough, and people can experience a significant decline in their quality of life, with their daily activities becoming more restricted as the condition progresses. People live on average for around three years after being diagnosed with IPF, but around one in five people with the condition will live for longer than five years.

There is currently no cure for IPF. Current treatment options, which are aimed at managing the condition and delaying its progression, include best supportive care and pirfenidone. Lung transplantation may also be considered. Nintedanib is a new drug for IPF. It is an orally administered, intracellular inhibitor of tyrosine kinases, and is thought to work by helping to delay the loss of lung function, thereby slowing the progression of the disease.

SHTAC is assessing the clinical and cost effectiveness evidence submitted by the company to NICE for nintedanib in the treatment of IPF. It is expected that NICE will issue guidance on the use of nintedanib for IPF in the NHS in January 2016. For more information about SHTAC’s previous research into IPF, please visit our Research page.

Privacy Settings